2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

José A. Joglar, Mina K. Chung, Anastasia L. Armbruster, Emelia J. Benjamin, Janice Y. Chyou, Edmond M. Cronin, Anita Deswal, Lee L. Eckhardt, Zachary D. Goldberger, Rakesh Gopinathannair, Bulent Gorenek, Paul L. Hess, Mark Hlatky, Gail Hogan, Chinwe Ibeh, Julia H. Indik, Kazuhiko Kido, Fred Kusumoto, Mark S. Link, Kathleen T. LintaGregory M. Marcus, Patrick M. McCarthy, Nimesh Patel, Kristen K. Patton, Marco V. Perez, Jonathan P. Piccini, Andrea M. Russo, Prashanthan Sanders, Megan M. Streur, Kevin L. Thomas, Sabrina Times, James E. Tisdale, Anne Marie Valente, David R. Van Wagoner

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)

Abstract

AIM: The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation” provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation. METHODS: A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.

Original languageEnglish
Pages (from-to)E1-E156
JournalCirculation
Volume149
Issue number1
DOIs
Publication statusPublished or Issued - 2 Jan 2024

Keywords

  • acute coronary syndrome
  • AHA Scientific Statements
  • alcohol
  • anticoagulants
  • anticoagulation agents
  • antiplatelet agents
  • apixaban
  • atrial fibrillation
  • atrial flutter
  • cardioversion
  • catheter ablation
  • coronary artery disease
  • coronary heart disease
  • dabigatran
  • edoxaban
  • exercise
  • heart failure
  • hypertension
  • idarucizumab
  • left atrial appendage occlusion
  • myocardial infarction
  • obesity
  • percutaneous coronary intervention
  • pulmonary vein isolation
  • risk factors
  • rivaroxaban
  • sleep apnea
  • stents
  • stroke
  • surgical ablation
  • thromboembolism
  • warfarin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this